• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Endocare

Endocare

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. UPDATE: These are the only 9 stocks Morningstar is fully bullish on

    UPDATE: These are the only 9 stocks Morningstar is fully bullish on

  2. Carl Marks Advisors Bolsters Investment Banking with Promotion of Scott Webb and David Endo

    Carl Marks Advisors Bolsters Investment Banking with Promotion of Scott Webb and David Endo

  3. Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Trial with long-acting growth hormone, GX-H9 at ENDO 2017

    Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Trial with long-acting growth hormone, GX-H9 at ENDO 2017

  4. Global Reprocessed Medical Devices Market Opportunity, Analysis, Market Shares 2017-2023: Key Players are Cardinal Health, Centurion Medical & GE Healthcare - Research and Markets

    Global Reprocessed Medical Devices Market Opportunity, Analysis, Market Shares 2017-2023: Key Players are Cardinal Health, Centurion Medical & GE Healthcare - Research and Markets

  5. UPDATE: Time for some game theory: A look at Jazz Pharma's latest settlement

    UPDATE: Time for some game theory: A look at Jazz Pharma's latest settlement

  6. Global $442.3 Billion Weight Management (Meals, Beverages, Supplements, Fitness Centers, Slimming Centers, Online Weight Loss Service) Market Analysis 2014-2017 & 2025 - Research and Markets

    Global $442.3 Billion Weight Management (Meals, Beverages, Supplements, Fitness Centers, Slimming Centers, Online Weight Loss Service) Market Analysis 2014-2017 & 2025 - Research and Markets

  7. UPDATE: Time for some game theory: A look at Jazz Pharma's latest settlement

    UPDATE: Time for some game theory: A look at Jazz Pharma's latest settlement

  8. UPDATE: Time for some game theory: A look at Jazz Pharma's latest settlement

    UPDATE: Time for some game theory: A look at Jazz Pharma's latest settlement

  9. Time for some game theory: A look at Jazz Pharma's latest settlement

    Time for some game theory: A look at Jazz Pharma's latest settlement

  10. The Market: Exaggerated Woes

    Endo Pharmaceuticals ENDP announced July 11 that it no longer expects to file a new drug application for its ketoprofen pain-relief patch by the first half of 2008 because of lackluster Phase III trial results. The drug candidate failed to show statistically significant results for pain relief in ...

12

©2017 Morningstar Advisor. All right reserved.